{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:29:52Z","timestamp":1770740992389,"version":"3.49.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,6]],"date-time":"2027-02-06T00:00:00Z","timestamp":1801872000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.017","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:22:09Z","timestamp":1761146529000},"page":"e157-e163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell Lymphomas"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.017_bib0001","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.clml.2025.10.017_bib0002","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-022-03404-6","article-title":"Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma","volume":"482","author":"King","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clml.2025.10.017_bib0003","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0004","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.10.017_bib0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2024024048","article-title":"Testing for t(3;8) in MYC\/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival","volume":"144","author":"Maybury","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0007","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.2020008374","article-title":"Defining and treating high-grade B-cell lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"NOS. Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0008","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1182\/bloodadvances.2025016651","article-title":"High-grade B-cell lymphoma, not otherwise specified: an LLMPP study","volume":"9","author":"Collinge","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0009","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","article-title":"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0010","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.24.00070","article-title":"Lymphoma classifications, how to develop a future unified taxonomy","volume":"42","author":"Campo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements","volume":"129","author":"Sesques","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0012","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0013","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ajcp\/aqae158","article-title":"How I diagnose high-grade B-cell lymphoma","volume":"163","author":"Moore","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2025.10.017_bib0014","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/PAS.0000000000001613","article-title":"A diagnostic approach to the identification of burkitt-like lymphoma with 11q aberration in aggressive B-cell lymphomas","volume":"45","author":"Horn","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2025.10.017_bib0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"Salaverria","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100774","article-title":"Cytogenomic and clinicopathologic comparison of MYC-positive and MYC-negative high-grade B-cell lymphoma with 11q aberration in the context of other aggressive lymphomas with MYC rearrangement","volume":"38","author":"Grygalewicz","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2025.10.017_bib0017","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0019","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0021","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of Bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0022","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/ajcp\/aqaf074","article-title":"An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomas","volume":"164","author":"Zhao","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2025.10.017_bib0023","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0024","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2025.10.017_bib0025","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2024025652","article-title":"DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma","volume":"145","author":"Chapuy","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0026","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.10.017_bib0027","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.017_bib0028","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1158\/1078-0432.CCR-20-2378","article-title":"Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP","volume":"27","author":"Song","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.10.017_bib0029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1541-7786.MCR-20-0466","article-title":"Aggressive B-cell lymphoma with MYC\/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents","volume":"19","author":"Deng","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clml.2025.10.017_bib0030","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome","volume":"107","author":"Dodero","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.017_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.27513","article-title":"High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: genomic analysis and potential therapeutics","volume":"100","author":"Lone","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.017_bib0032","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0033","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0034","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0035","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0036","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/asheducation-2014.1.107","article-title":"Double-hit lymphomas: current paradigms and novel treatment approaches","volume":"2014","author":"Dunleavy","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2025.10.017_bib0037","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjh.12901","article-title":"Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients","volume":"166","author":"Landsburg","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.10.017_bib0038","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.10.017_bib0039","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0040","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0041","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024025725","article-title":"CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL","volume":"145","author":"Alduaij","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0042","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1182\/bloodadvances.2024013791","article-title":"High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series","volume":"8","author":"Epperla","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0043","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","volume":"137","author":"Ollila","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0044","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell Lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0045","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2021-145954","article-title":"Population-wide introduction of dose-adjusted EPOCH-R is associated with improved outcome of high grade B-cell lymphoma with MYC and BCL2 rearrangements with diffuse large B-cell lymphoma morphology","volume":"138","author":"Alduaij","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.10.017_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70139","article-title":"Biomarker-adapted treatment in high-risk large B-cell lymphoma","volume":"9","author":"Leppa","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.10.017_bib0048","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/bloodadvances.2019000875","article-title":"Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics","volume":"4","author":"Torka","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0049","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2021-151266","article-title":"Randomized phase II\/III study of DA-EPOCH-R \u00b1 venetoclax in previously untreated double hit lymphoma: initial results from Alliance A051701","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00022-3","article-title":"Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial","volume":"8","author":"Frontzek","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.10.017_bib0051","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.10.017_bib0052","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0053","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0054","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.017_bib0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41408-023-00854-2","article-title":"A nonrandomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients","volume":"13","author":"de Jonge","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.017_bib0056","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1182\/bloodadvances.2022007475","article-title":"Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma","volume":"6","author":"Ferreri","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0057","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.017_bib0058","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood.2023022048","article-title":"Cell-of-origin effect of Polatuzumab Vedotin in diffuse large B-Cell lymphoma: no ordinary subgroup analysis","volume":"142","author":"Russler-Germain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0059","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2023-178623","article-title":"Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70110_LBA1","article-title":"LBA1 | the benefit of POLA-R-CHP in DLBCLASS-defined molecular subsets of newly diagnosed DLBCL in the Polarix Trial","volume":"43","author":"Calabretta","year":"2025","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0061","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/2643-3230.BCD-25-0099","article-title":"B-cell receptor silencing reveals the origin and dependencies of high-grade B-cell lymphomas with MYC and BCL2 rearrangements","volume":"6","author":"Varano","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.10.017_bib0062","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood.2022016226","article-title":"CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights","volume":"140","author":"Ali","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0063","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.017_bib0064","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.017_bib0065","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0066","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2023-183001","article-title":"Improved survival of R\/R double hit\/triple hit lymphoma in the era of CD19 chimeric antigen T Cell (CART) therapy","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0067","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-025-01250-8","article-title":"Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy","volume":"15","author":"Karmali","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.017_bib0068","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.017_bib0069","first-page":"P1239","article-title":"Response in molecular subgroups and circulating tumor (CT)DNA kinetics in patients with relapsed and\/or refractory (R\/R) large B-cell lymphoma (LBCL) treated with glofitamab\u25bc monotherapy","author":"Carlo-Stella","year":"2024","journal-title":"EHA abstract"},{"key":"10.1016\/j.clml.2025.10.017_bib0070","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.10.017_bib0071","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2025.10.017_bib0072","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large B cell lymphoma microenvironment archetype profiles","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2025.10.017_bib0073","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Broske","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0074","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/bloodadvances.2023011687","article-title":"Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC\/BCL2 vs patients with DLBCL NOS","volume":"8","author":"de Jonge","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.017_bib0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01957","article-title":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial","author":"Budde","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.017_bib0076","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.017_bib0077","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.017_bib0078","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:18:00Z","timestamp":1770650280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042594"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}